Siew Eng Choon
YOU?
Author Swipe
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors Open
Psoriasis experts reached consensus that routine testing for latent TB infection is not required in psoriasis patients being treated with IL-17 or IL-23 inhibitors.
View article: Global Delphi consensus on treatment goals for generalized pustular psoriasis
Global Delphi consensus on treatment goals for generalized pustular psoriasis Open
Background Generalized pustular psoriasis (GPP) is a chronic, systemic, neutrophilic inflammatory disease. A previous Delphi panel established areas of consensus on GPP, although patient perspectives were not included and aspects of treatm…
View article: Asia‐Pacific consensus recommendations on the management of generalized pustular psoriasis
Asia‐Pacific consensus recommendations on the management of generalized pustular psoriasis Open
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogeneous, and potentially life‐threatening disease characterized by primary, sterile, and macroscopically visible pustules with or without systemic symptoms. There are ethnic di…
View article: Low Occurrence of Predefined Safety Events Across Six Randomized Clinical Trials of Spesolimab in Dermatologic Conditions
Low Occurrence of Predefined Safety Events Across Six Randomized Clinical Trials of Spesolimab in Dermatologic Conditions Open
Introduction In the randomized, placebo-controlled Effisayil 2 trial, the anti-interleukin (IL)-36 receptor antibody spesolimab demonstrated a reassuring safety profile when given over 48 weeks for flare prevention in patients with general…
View article: Spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil <sup>™</sup> 2 study
Spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil <sup>™</sup> 2 study Open
What is this study about?: \nGeneralized pustular psoriasis (shortened to GPP) is a rare, potentially life-threatening disease in which pus-filled blisters or pustules may suddenly form all over the body. The drug spesolimab has been appro…
View article: Effect of Subcutaneous Spesolimab on the Prevention of Generalized Pustular Psoriasis Flares Over 48 weeks: Subgroup Analyses from the Effisayil 2 Trial
Effect of Subcutaneous Spesolimab on the Prevention of Generalized Pustular Psoriasis Flares Over 48 weeks: Subgroup Analyses from the Effisayil 2 Trial Open
Introduction: Generalized pustular psoriasis (GPP) is characterized by flares of widespread pustulation and erythema that may be fatal. Spesolimab, an anti-interleukin-36 receptor monoclonal antibody, is approved to treat GPP flares. Effis…
Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice Open
Importance Although several clinician- and patient-reported outcome measures have been developed for trials in hidradenitis suppurativa (HS), there is currently no consensus on which measures are best suited for use in clinical practice. I…
Health‐related quality of life in patients with generalized pustular psoriasis: A systematic literature review Open
Generalized pustular psoriasis (GPP) is a rare, chronic, neutrophilic inflammatory skin disease characterized by episodes of widespread eruption of sterile, macroscopic pustules that can be accompanied by systemic inflammation and symptoms…
Cover Image Open
Figure 1. Geographic tongue which is more prevalent in GPP patients with IL36RN mutations is based on the Research Article Clinical profile of patients with acute generalized pustular psoriasis with and without IL36RN mutations in multi-et…
Understanding generalized pustular psoriasis for improved patient care Open
SEC declared paid activities as advisor, speaker or consultant for AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, Leo, Pharma, MSD, Novartis, Pfizer, Sanofi, Almirall and UCB. JB received consultancy fees and grants from AbbVie, Almiral…
Incidence and prevalence of generalized pustular psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in the Teleprimary Care (TPC®) clinical information system from 2010 to 2020 Open
Background There is limited understanding of the epidemiology of generalized pustular psoriasis (GPP) internationally, with no population-based estimates of GPP in South East Asia. Objectives To determine the incidence and prevalence of GP…
Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre‐specified patient subgroups in the Effisayil 1 study Open
Effisayil 1 was a multicentre, randomized, double‐blind, placebo‐controlled study of the anti‐interleukin (IL)‐36 receptor monoclonal antibody, spesolimab, in patients presenting with a generalized pustular psoriasis (GPP) flare. Previousl…
View article: The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity Open
Generalized pustular psoriasis (GPP), a rare and potentially life-threatening neutrophilic skin disease, is characterized by recurrent flares of pustulation on nonacral skin with associated erythema, crusting and scaling. There are no agre…
Diversity in the clinical presentation of generalized pustular psoriasis (<span>GPP</span>): A series of case vignettes from around the world Open
A key principle of clinical studies and case reports is that they should reflect the demographics and epidemiology of the patient population concerned. Here, we have compiled a diverse group of clinical cases of generalized pustular psoria…
Clinical profile of patients with acute generalized pustular psoriasis with and without <span>IL36RN</span> mutations in multi‐ethnic Johor Bahru, Malaysia Open
Generalized Pustular psoriasis (GPP), a rare and potentially life‐threatening auto‐inflammatory disease, is associated with IL36RN mutations. Here, we analyse the prevalence of IL36RN mutations in our multi‐ethnic GPP cohort and assess dif…
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management Open
Background Generalized pustular psoriasis (GPP) is a rare and highly heterogeneous skin disease, characterized by flares of neutrophilic pustules and erythema. As a rare disease with few clinical studies and no standardized management appr…
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares Open
Background: Generalized pustular psoriasis (GPP) is a rare, neutrophilic skin disease that can become life-threatening if flares are untreated. There are limited data describing the characteristics and clinical course of GPP disease flares…
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis Open
NCT04399837.
View article: Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review
Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review Open
Generalized pustular psoriasis (GPP) is a rare auto‐inflammatory skin disease characterised by acute episodes of sterile pustule formation. Diagnosis and treatment of the disease have historically been complicated by a lack of awareness, a…
Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double‐blind, placebo‐controlled Effisayil™ 1 study Open
Generalized pustular psoriasis is a potentially life‐threatening neutrophilic skin disease characterized by recurrent flares of widespread erythema and eruption of sterile pustules. In the Effisayil™ 1 study (NCT03782792), 53 patients with…
Incidence and prevalence of psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in the Teleprimary Care (TPC®) clinical information system from 2010 to 2020 Open
Summary Background There are no population-based epidemiological data on psoriasis in Southeast Asia, including Malaysia. Objectives To determine the incidence and prevalence of psoriasis over 11 years in multiethnic Johor Bahru, Malaysia.…
Spesolimab Treatment for People with Flares of Generalized Pustular Psoriasis: A Plain Language Summary of the Effisayil™ 1 Study Open
What is this study about?: Spesolimab is a drug developed to treat worsening disease (known as flares) of generalized pustular psoriasis (shortened to GPP). GPP is a rare disease in which pus-filled blisters or pustules suddenly form all o…
Clinical Course and Characteristics of Generalized Pustular Psoriasis Open
Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterized by episodes of widespread sterile macroscopic pustules, with or without systemic inflammation and/or plaque psoriasis. Multiple GPP subtypes…